Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review
Oncology Today with Dr Neil Love
00:00
HER2 expression and ADC patient selection
Terence discusses broad HER2 eligibility (1+ to 3+), response rates, and uncertainty over which HER2 levels guide DV versus EV.
Play episode from 09:44
Transcript
